Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Mereo Biopharma Group Plc (MREO)
NASDAQ:MREO
RESEARCH TOOLSreports
Holding MREO?
Track your performance easily
MREO Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.86 - $5.02
Previous Close$3.72
Volume1.13M
Average Volume (3M)743.52K
Market Cap
$575.61M
Enterprise Value$524.90M
Total Cash (Recent Filing)£45.10M
Total Debt (Recent Filing)£5.14M
Price to Earnings (P/E)―
Beta1.63
Next Earnings
Mar 26, 2025EPS Estimate
$0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.25
Shares Outstanding154,734,459
10 Day Avg. Volume1,058,065
30 Day Avg. Volume743,525
Standard Deviation0.34
R-Squared0.02
Alpha0.04
Financial Highlights & Ratios
Price to Book (P/B)10.23
Price to Sales (P/S)46.15
Price to Cash Flow (P/CF)-41.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$7.25Price Target Upside114.50% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Mereo Biopharma Group Plc News
PremiumCompany Announcements
Mereo BioPharma: Strong Cash Position Amid Clinical Progress
PremiumCompany Announcements
Mereo BioPharma’s Public Offering and Strategic Underwriter Partnership
Ownership Overview
1.70% Insiders
0.10% Mutual Funds
51.35% Other Institutional Investors
46.25% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
MREO FAQ
What was Mereo Biopharma Group Plc’s price range in the past 12 months?
Mereo Biopharma Group Plc lowest stock price was $1.86 and its highest was $5.02 in the past 12 months.
What is Mereo Biopharma Group Plc’s market cap?
Currently, no data Available
When is Mereo Biopharma Group Plc’s upcoming earnings report date?
Mereo Biopharma Group Plc’s upcoming earnings report date is Mar 26, 2025 which is in 120 days.
How were Mereo Biopharma Group Plc’s earnings last quarter?
Mereo Biopharma Group Plc released its earnings results on Nov 12, 2024. The company reported -$0.02 earnings per share for the quarter, missing the consensus estimate of -$0.018 by -$0.002.
Is Mereo Biopharma Group Plc overvalued?
According to Wall Street analysts Mereo Biopharma Group Plc’s price is currently Undervalued.
Does Mereo Biopharma Group Plc pay dividends?
Mereo Biopharma Group Plc does not currently pay dividends.
What is Mereo Biopharma Group Plc’s EPS estimate?
Mereo Biopharma Group Plc’s EPS estimate is $0.01.
How many shares outstanding does Mereo Biopharma Group Plc have?
Mereo Biopharma Group Plc has 155,145,600 shares outstanding.
What happened to Mereo Biopharma Group Plc’s price movement after its last earnings report?
Mereo Biopharma Group Plc reported an EPS of -$0.02 in its last earnings report, missing expectations of -$0.018. Following the earnings report the stock price went down -4.206%.
Which hedge fund is a major shareholder of Mereo Biopharma Group Plc?
Among the largest hedge funds holding Mereo Biopharma Group Plc’s share is Deerfield Management Company, LP. It holds Mereo Biopharma Group Plc’s shares valued at 28M.
---
Mereo Biopharma Group Plc Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.25 (114.50% Upside)
$7.25 (114.50% Upside)
Blogger Sentiment
Neutral
MREO Sentiment 50%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 424.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $533.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.0%
Last 30 Days ▼ 6.0%
Last 30 Days ▼ 6.0%
Company Description
Mereo Biopharma Group Plc
Mereo BioPharma Group Plc engages in the acquisition, development, and commercialization of innovative therapeutics that aim to improve outcomes for patients with rare and specialty diseases. It focuses on the treatment of patients with Osteogenesis Imperfecta, Alpha-1 Antitrypsin Deficiency, Hypogonadotropic Hypogonadism in obese men, and Acute Exacerbations of Chronic Obstructive Pulmonary Disease. The company was founded by Denise Vera Pollard-Knight, Charles Sermon, Alastair MacKinnon, and John Richard in March 2015 and is headquartered in London, the United Kingdom.
---
MREO Stock 12 Month Forecast
Average Price Target
$7.25
▲(114.50% Upside)
Technical Analysis
Best Analysts Covering MREO
1 Year
1 Year Success Rate
12/16 ratings generated profit
1 Year Average Return
+84.90%
reiterated a buy rating 15 days ago
Copying Joseph Schwartz's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +84.90% per trade.
---